Tag: NOX
Noxopharm’s idronoxil could potentially prevent COVID-19 fatalities, clinical trials to begin
Noxopharm (ASX: NOX) is the latest small cap to reveal it has a potential COVID-19 treatment, after it reported this morning its advanced idronoxil drug could block an excessive inflammatory response ...
Noxopharm receives FDA investigational new drug approval for Veyonda
Oncology drug development company Noxopharm (ASX: NOX) has received FDA investigational new drug (IND) approval for using its Veyonda in combination with doxorubicin to treat patients with soft tissue...
Noxopharm reports positive interim clinical trial results for cancer drug Veyonda
Biotech company Noxopharm’s (ASX: NOX) came out of a trading halt this morning with positive interim results from its LuPIN phase I/II clinical trial into end-stage prostate cancer.
The LuPIN study...
Noxopharm’s US biotech subsidiary Nyrada IPO successfully raises $8.5m
Australian biotech Noxopharm’s (ASX: NOX) US spin-off Nyrada Inc (ASX: NYR) experienced strong demand in its initial public offering and will now make its ASX debut today after successfully raising $8...
Noxopharm clinical data shows potential for major new treatment of late-stage prostate cancer
Biotech drug developer Noxopharm (ASX: NOX) has reported positive end-of-study results from its DARRT-1 phase 1b trial treating men with late-stage prostate cancer.
In an update yesterday, the onco...
Noxopharm confirms durable anti-cancer effect from lead drug Veyonda
Anti-cancer drug developer Noxopharm (ASX: NOX) has set the stage to present its highly-anticipated clinical data to the Clinical Oncology Society of Australia by publishing interim data from a DARRT-...
Noxopharm releases positive interim results from prostate cancer drug study using radioactive therapy
Australian biotech drug developer Noxopharm (ASX: NOX) has reported positive interim results from its LuPIN study involving the Veyonda drug developed for men with late stage metastatic, castration-re...
Noxopharm reports interim ‘clinical benefits’ in treating prostate cancer with Veyonda
Noxopharm (ASX: NOX) has reported interim clinical benefits from an ongoing 24-week trial combining its Veyonda drug with radiotherapy in treating prostate cancer patients.
Previously known as NOX6...
Noxopharm and Nyrada discover ‘major development’ for treatment of autoimmune diseases
Biotech drug developer Noxopharm (ASX: NOX) has made an important drug discovery which could potentially help the company develop a treatment that mitigates the effects of autoimmune diseases.
Acco...
Pre-clinical data suggests Noxopharm’s anti-cancer drug can boost radiation effect on paediatric brain cancer
Pre-clinical data has confirmed Noxopharm’s (ASX: NOX) experimental idronoxil anti-cancer drug can boost the killing effect of radiation when treating paediatric brain cancer cells.
Noxopharm teame...
Noxopharm hopeful tumour treatment can help reverse late-stage metastatic cancer
Chief executive Dr Graham Kelly has shared his hope drug developer Noxopharm’s (ASX: NOX) NOX66 therapeutic could be a major advance in the treatment of late-stage cancers that have spread to other pa...
Noxopharm looks to remove toxic assumptions from chemotherapy
Biotech drug developer Noxopharm (ASX: NOX) has presented its most-recent clinical data from its groundbreaking CEP-1 clinical study, at the ESMO International Congress on Targeted Anticancer Therapie...
Noxopharm to commence NOX66 cancer study at St Vincent’s Hospital
Noxopharm (ASX: NOX) has announced the involvement of its experimental drug, NOX66, in a clinical study looking at the ability of a pioneering form of radiotherapy to boost survival prospects in men w...
